Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04437303
Other study ID # NL73805.100.20
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date November 25, 2020
Est. completion date May 22, 2024

Study information

Verified date May 2024
Source St. Antonius Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Transcatheter aortic valve implantation (TAVI) is a rapidly growing treatment option for patients with aortic valve stenosis. Stroke is a feared complication of TAVI, with an incidence of around 4-5% in the first 30 days. Up to 50% of patients undergoing TAVI have an indication for oral anticoagulants (OAC) mostly for atrial fibrillation. OAC use during TAVI could increase bleeding complications, but interruption during TAVI may increase the risk for thromboembolic events (i.e. stroke, systemic embolism, myocardial infarction). Recent observational data suggest that periprocedural continuation of OAC is safe and might decrease the risk of stroke. Beside the potential reduction of thromboembolic events, continuation of OAC is associated with an evident clinical ancillary benefit for patients and staff. Since periprocedural OAC interruption not infrequently leads to misunderstanding and potentially dangerous situations, when patients are not properly informed before hospital admission or may experience difficulties with the interruption regimen. Hypothesis: Periprocedural continuation of oral anticoagulants is safe and might decrease thromboembolic complications without an increase in bleeding complications at 30 days


Recruitment information / eligibility

Status Completed
Enrollment 858
Est. completion date May 22, 2024
Est. primary completion date March 21, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Planned transfemoral or transsubclavian transcatheter aortic valve implantation procedure - Uses oral anticoagulation at screening - Provided written informed consent Exclusion Criteria: Patients at high risk for thromboembolism for whom interruption of oral anticoagulants is no option, i.e.: - Mechanical heart valve prosthesis - Intracardiac thrombus - < 3 months after venous thromboembolism - < 6 months after transient ischemic attack or stroke in patients with atrial fibrillation

Study Design


Intervention

Drug:
Continuation of oral anticoagulants
Oral anticoagulant treatment will not be interrupted before the procedure.
Interruption of oral anticoagulants
Peri-operative interruption of oral anticoagulants will be according to the Dutch guideline on antithrombotic therapy. For direct oral anticoagulant users this will be in general 48 hours before the procedure, except for Dabigatran users with renal insufficiency: with estimated glomerular filtration rate 50-80 mL/min/1.73m^2 72 hours and with estimated glomerular filtration rate 30-50 mL/min/1.73m^2 96 hours before procedure. For vitamin K antagonist users this will be 5 days for phenprocoumon and 3 days for acenocoumarol. After the procedure oral anticoagulants will be resumed after 24 hours, if deemed safe by the treating physician.

Locations

Country Name City State
Belgium A.S.Z. Hospital Aalst
Belgium O.L.V. Hospital Aalst
Belgium ZNA Middelheim Antwerp
Belgium AZ Sint-Jan Brugge
Belgium East Limburg Hospital Genk
Belgium University Hospital Leuven Leuven
Belgium AZ Delta Roeselare
Denmark Rigshospitalet Copenhagen Copenhagen
Ireland University Hospital Galway Galway
Italy Azienda Sanitaria Universitaria Integrata di Trieste Trieste
Luxembourg National Institute of Cardiac Surgery and Interventional Cardiology Luxembourg
Netherlands Amsterdam UMC Amsterdam
Netherlands Amphia Hospital Breda
Netherlands UMC Groningen Groningen
Netherlands Leiden University Medical Center Leiden
Netherlands Maastricht UMC+ Maastricht
Netherlands St. Antonius Ziekenhuis Nieuwegein Utrecht
Netherlands Radboud UMC Nijmegen
Netherlands Erasmus MC Rotterdam
Netherlands Haga Hospital The Hague
Netherlands UMC Utrecht Utrecht
Netherlands Isala Zwolle

Sponsors (1)

Lead Sponsor Collaborator
St. Antonius Hospital

Countries where clinical trial is conducted

Belgium,  Denmark,  Ireland,  Italy,  Luxembourg,  Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other New York Heart Association class for heart failure 30 days
Other Rehospitalisation 30 days
Other Permanent pacemaker implantation 30 days
Other Bleeding As classified by Bleeding Academic Research Consortium (BARC) criteria 30 days
Primary Net adverse clinical events A composite of cardiovascular mortality, all stroke, myocardial infarction, major vascular complications and type 2-4 bleeding complications at 30 days post TAVI as defined by the VARC-3 criteria 30 days
Secondary Procedure related primary endpoints Cardiovascular mortality, all stroke, myocardial infarction, major vascular complications and type 2-4 bleeding complications as defined by the VARC-3 criteria considered procedure related as adjudicated by the clinical event committee 30 days
Secondary Procedure related bleeding complications Type 1-4 bleeding as defined by the VARC-3 criteria considered procedure related as adjudicated by the clinical event committee 30 days
Secondary Procedure related thromboembolic complications All stroke (except haemorrhagic), TIA, myocardial infarction, systemic embolism (vascular complications: distal embolization (non-cerebral) from a vascular source) as defined by the VARC-3 criteria considered procedure related as adjudicated by the clinical event committee 30 days
Secondary Thromboembolic complications All stroke (except haemorrhagic), TIA, myocardial infarction and systemic embolism (vascular complications: distal embolization (non-cerebral) from a vascular source) as defined by the VARC-3 criteria 30 days
Secondary Neurologic events Overt CNS injury, covert CNS injury, neurologic dysfunction (acutely symptomatic) without CNS injury as defined by the VARC-3 criteria 30 days
Secondary Cerebrovascular events All stroke and TIA as defined by the VARC-3 criteria. 30 days
Secondary Stroke All stroke as defined by the VARC-3 criteria 30 days
Secondary Bleeding complications Type 1-4 bleeding as defined by the VARC-3 criteria 30 days
Secondary Early safety Freedom from all-cause mortality, all stroke, VARC type 2-4 bleeding, major vascular, access-related, or cardiac structural complication, acute kidney injury stage 3 or 4, moderate or severe aortic regurgitation, new permanent pacemaker due to procedure related conduction abnormalities, surgery or intervention related to the device as defined by the VARC-3 criteria 30 days
Secondary Clinical efficacy Freedom from: all-cause mortality, all stroke, hospitalization for procedure- or valve-related causes, KCCQ Overall Summary Score <45 or decline from baseline of >10 point as defined by the VARC-3 criteria 30 days
Secondary All-cause death 30 days
Secondary Cardiovascular death 30 days
Secondary Quality of Life Assessed by Short Form(SF)-12, Kansas City Cardiomyopathy Questionnaire (KCCQ), and Toronto aortic stenosis quality of life questionnaire (TASQ) 30 days and 90 days
See also
  Status Clinical Trial Phase
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Recruiting NCT03869138 - Alternative Therapies for Improving Physical Function in Individuals With Stroke N/A
Completed NCT04101695 - Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects N/A
Completed NCT04034069 - Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Completed NCT00391378 - Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS) N/A
Recruiting NCT06204744 - Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial N/A
Active, not recruiting NCT06043167 - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Active, not recruiting NCT04535479 - Dry Needling for Spasticity in Stroke N/A
Completed NCT03985761 - Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke N/A
Recruiting NCT00859885 - International PFO Consortium N/A
Recruiting NCT06034119 - Effects of Voluntary Adjustments During Walking in Participants Post-stroke N/A
Completed NCT03622411 - Tablet-based Aphasia Therapy in the Chronic Phase N/A
Completed NCT01662960 - Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke N/A
Recruiting NCT05854485 - Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke N/A
Active, not recruiting NCT05520528 - Impact of Group Participation on Adults With Aphasia N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT05805748 - Serious Game Therapy in Neglect Patients N/A
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT05621980 - Finger Movement Training After Stroke N/A